Mantle Cell Lymphoma

Latest News

$CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.$

February 26th 2021

CD19-Targeted CAR T-Cell Therapies Induce Durable Remissions in Several Lymphoma Subtypes

By Hayley Virgil

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

February 24th 2021

KTE-X19 Continues to Elicit Durable Responses in Relapsed/Refractory MCL

By Kristi Rosa

$Sattva Neelapu, MD, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma.$

February 24th 2021

Dr. Neelapu on Emerging CAR T-Cell Therapies in Relapsed/Refractory MCL

By Sattva Neelapu, MD

February 23rd 2021

Ibrutinib/Venetoclax Demonstrates Encouraging Efficacy in Relapsed/Refractory MCL

By Courtney Marabella

February 23rd 2021

MCL: Emerging BTKi-Combination Approaches

By John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine, Krish Patel, MD, Swedish Medical Center, Tycel Jovelle Phillips, MD, University of Michigan

Latest Videos

Dr. Danilov on the Differences Between Covalent and Noncovalent BTK Inhibitors in MCL

Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCL

Dr. Kahl on the Current Unmet Needs in MCL

Dr. Phillips on p53 Mutations in MCL

Dr. Kahl on the Evolving Standard of Care in MCL

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD

Dr. Eyre on the Design of the BRUIN-MCL-321 Trial in MCL

Dr. Yang on the Current Treatment Landscape in MCL

Inside the Clinic: Experts Highlight Molecular Complexities in MCL

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL

Dr. Dietrich on the Current Treatment Landscape of MCL

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Munaf Alkadimi, MD

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

Shaina Rozell, MD, MPH; Seth A. Wander, MD, PhD

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Register now!

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Video

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

In-Person + Virtual Event

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

March 24, 2026

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Video

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

Video

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

In-Person + Virtual Event

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

February 19, 2026

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

More News

Emerging BTK Inhibitors in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 23rd 2021

Hun Ju Lee, MD, of The University of Texas MD Anderson Cancer Center

Dr. Lee on Potential Challenges With VLS-101 in MCL and DLBCL

ByHun Ju Lee, MD

February 22nd 2021

Hun Ju Lee, MD, discusses potential challenges with VLS-101 in mantle cell lymphoma and diffuse large B-cell lymphoma.

Dr. Jain on the Safety Profile of Ibrutinib/Rituximab in MCL

ByPreetesh Jain, MD, PhD

February 20th 2021

Preetesh Jain, MD, PhD, discusses the safety profile of combination ibrutinib and rituximab in patients with mantle cell lymphoma.

Dr. Dean on the Potential Role of Consolidative CAR T-Cell Therapy in MCL

ByRobert Dean, MD

February 18th 2021

Robert M. Dean, MD, discusses the potential role for consolidative CAR T-cell therapy in mantle cell lymphoma.

Jia Ruan, MD, PhD, of Weill Cornell Medicine/NewYork-Presbyterian Hospital

Dr. Ruan on the Future of Lenalidomide/Rituximab in MCL

ByJia Ruan, MD, PhD

February 17th 2021

Jia Ruan, MD, PhD, discusses the future evaluation of lenalidomide plus rituximab in mantle cell lymphoma.

Dr. Lee on the Potential Utility of Ibrutinib/Cirmtuzumab in MCL

ByHun Ju Lee, MD

February 16th 2021

Hun Ju Lee, MD, discusses the potential utility of ibrutinib in combination with cirmtuzumab in mantle cell lymphoma.

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 16th 2021

Venetoclax in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 16th 2021

Preetesh Jain, MD, PhD, of The University of Texas MD Anderson Cancer Center

Dr. Jain on the Efficacy of Ibrutinib/Rituximab in MCL

ByPreetesh Jain, MD, PhD

February 15th 2021

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib plus rituximab in mantle cell lymphoma.

Dr. Ruan on the Long-Term Benefits of Lenalidomide/Rituximab in MCL

ByJia Ruan, MD, PhD

February 12th 2021

Jia Ruan, MD, PhD, discusses the long-term benefits of lenalidomide plus rituximab in mantle cell lymphoma.

$Amitkumar Mehta, MD, discusses the rationale behind utilizing parsaclisib in relapsed or refractory mantle cell lymphoma as part of the phase 2 CITADEL-205 study.$

Dr. Mehta on the Rationale for Utilizing Parsaclisib in Relapsed or Refractory MCL

ByAmitkumar Mehta, MD

February 12th 2021

Amitkumar Mehta, MD, discusses the rationale behind utilizing parsaclisib in relapsed or refractory mantle cell lymphoma as part of the phase 2 CITADEL-205 study.

BTK Inhibitors for Relapsed MCL: Important Considerations

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 9th 2021

Selecting a BTKi for Relapsed MCL Treatment

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 9th 2021

Acalabrutinib and Zanubrutinib for Relapsed MCL

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 2nd 2021

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 2nd 2021

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 26th 2021

Go-To Treatment Regimens in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 26th 2021

Treatment Approaches in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 19th 2021

Accurately Diagnosing Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 19th 2021

$relapsed/refractory mantle cell lymphoma$

Interrupting Venetoclax Triplet After MRD Negativity Is Feasible in Relapsed/Refractory Mantle Cell Lymphoma

ByWayne Kuznar

January 12th 2021

January 12, 2021 - Stopping combination treatment with venetoclax, lenalidomide, and rituximab after achieving minimal residual disease negativity in patients with relapsed/refractory mantle cell lymphoma is feasible.

Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL

ByHun Ju Lee, MD

January 8th 2021

Hun Ju Lee, MD, discusses the tolerability of ibrutinib plus cirmtuzumab in mantle cell lymphoma and chronic lymphocytic lymphoma.

Javier L. Munoz, MD, Director of the Lymphoma Program at Mayo Clinic

Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

ByRachel Narozniak, MA,Jason Harris

January 8th 2021

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval

ByJessica Hergert

January 6th 2021

James Gerson, MD, discusses the introduction of CAR T-cell therapy to the mantle cell lymphoma armamentarium and how induction therapy followed by stem cell transplant has maintained a role.

Jia Ruan, MD, PhD, of Weill Cornell Medicine

Dr. Ruan on Updated Results With Lenalidomide/Rituximab in MCL

ByJia Ruan, MD, PhD

January 4th 2021

Jia Ruan, MD, PhD, discusses updated results with the combination of lenalidomide and rituximab in mantle cell lymphoma.

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib and rituximab in elderly patients with previously untreated mantle cell lymphoma.

Dr. Jain on the Responses Elicited With Ibrutinib/Rituximab in Previously Untreated MCL

ByPreetesh Jain, MD, PhD

December 24th 2020

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib and rituximab in elderly patients with previously untreated mantle cell lymphoma.

Mantle Cell Lymphoma

Latest News

Latest Videos

Dr. Danilov on the Differences Between Covalent and Noncovalent BTK Inhibitors in MCL

Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCL

Dr. Kahl on the Current Unmet Needs in MCL

Dr. Phillips on p53 Mutations in MCL

Dr. Kahl on the Evolving Standard of Care in MCL

Dr. Eyre on the Design of the BRUIN-MCL-321 Trial in MCL

Dr. Yang on the Current Treatment Landscape in MCL

Inside the Clinic: Experts Highlight Molecular Complexities in MCL

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL

Dr. Dietrich on the Current Treatment Landscape of MCL

CME Content

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

More News

Emerging BTK Inhibitors in Mantle Cell Lymphoma

Dr. Lee on Potential Challenges With VLS-101 in MCL and DLBCL

Dr. Jain on the Safety Profile of Ibrutinib/Rituximab in MCL

Dr. Dean on the Potential Role of Consolidative CAR T-Cell Therapy in MCL

Dr. Ruan on the Future of Lenalidomide/Rituximab in MCL

Dr. Lee on the Potential Utility of Ibrutinib/Cirmtuzumab in MCL

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

Venetoclax in Mantle Cell Lymphoma

Dr. Jain on the Efficacy of Ibrutinib/Rituximab in MCL

Dr. Ruan on the Long-Term Benefits of Lenalidomide/Rituximab in MCL

Dr. Mehta on the Rationale for Utilizing Parsaclisib in Relapsed or Refractory MCL

BTK Inhibitors for Relapsed MCL: Important Considerations

Selecting a BTKi for Relapsed MCL Treatment

Acalabrutinib and Zanubrutinib for Relapsed MCL

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

Go-To Treatment Regimens in Mantle Cell Lymphoma

Treatment Approaches in Mantle Cell Lymphoma

Accurately Diagnosing Mantle Cell Lymphoma

Interrupting Venetoclax Triplet After MRD Negativity Is Feasible in Relapsed/Refractory Mantle Cell Lymphoma

Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL

Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval

Dr. Ruan on Updated Results With Lenalidomide/Rituximab in MCL

Dr. Jain on the Responses Elicited With Ibrutinib/Rituximab in Previously Untreated MCL

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma